Dendritic cells in irradiated mice trigger the functional plasticity and antitumor activity of adoptively transferred Tc17 cells via IL12 signaling

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2546-2557

  Bowers, Jacob S ^a   Nelson, Michelle H ^a   Kundimi, Sreenath ^a   Bailey, Stefanie R ^a   Huff, Logan W ^a   Schwartz, Kristina M ^a   Cole, David J ^a   Rubinstein, Mark P ^a   Paulos, Chrystal M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IL17A+ CD9+ T CELL; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MELANOMA; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PLASTICITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; WHOLE BODY RADIATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD8+ T LYMPHOCYTE; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; RADIATION RESPONSE; SECRETION (PROCESS); T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; WHOLE-BODY IRRADIATION;

EID: 84935918600     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2294     Document Type: Article

References (53)

1. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011;25: 2559-72.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
3. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
4. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-81.
5. + T cells. J Exp Med 2005;202:907-12.
6. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
7. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66.
8. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007;117:2197-204.
9. Huang J, Wang QJ, Yang S, Li YF, El-Gamil M, Rosenberg SA, et al. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J Immunother 2011;34:327-35.
10. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010;59:137-48.
11. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
12. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2010;2:55ra78.
13. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
14. + T cells display enhanced antitumor immunity. Blood 2009;114:596-9.
15. + T cell lineage differentiation. Immunity 2009;30:646-55.
16. Tan C, Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol 2012;32:1-10.
17. Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV, et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol 2009;183:7161-8.
18. Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, et al. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol 2013;190:1873-81.
19. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 2010;184: 4215-27.
20. Nurieva R, Yang XO, Chung Y, Dong C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol 2009;182:2565-8.
21. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, et al. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 2007;117:492-501.
22. + T cells in vitro obviates the requirement for in vivo vaccination. Blood 2009;114:1776-83.
23. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 2007;13: 5280-9.
24. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010;33:1-7.
25. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
26. + T cell-mediated acute graftversus-host disease. J Clin Invest 2002;109:1335-44.
27. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011;19:751-9.
28. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011;121:4746-57.
29. Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 2013;21:1369-77.
30. Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J Mol Biol 2008;382: 931-41.
31. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008;181:5948-55.
32. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002;295:338-42.
33. + T helper cells. Cell 2006;126:1121-33.
34. + T cell differentiation. J Immunol 2006;177: 7515-9.
35. Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. Curr Opin Immunol 2013;25:556-63.
36. + T cells. J Immunol 2009;182:5296-305.
37. Kerkar SP, Restifo NP. The power and pitfalls of IL-12. Blood 2012;119: 4096-7.
38. Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 2006;176:5213-22.
39. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
40. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013;190:2415-23.
41. Veenstra KG, Jonak ZL, Trulli S, Gollob JA. IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma. J Immunol 2002;168:2282-7.
42. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-90.
43. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998;161:3400-7.
44. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004;10:5432-8.
45. Mukasa R, Balasubramani A, Lee YK, Whitley SK, Weaver BT, Shibata Y, et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 2010;32: 616-27.
46. Satoh T, Tajima M, Wakita D, Kitamura H, Nishimura T. The development of IL-17/IFN-gamma-double producing CTLs from Tc17 cells is driven by epigenetic suppression of Socs3 gene promoter. Eur J Immunol 2012;42: 2329-42.
47. + T cells. J Exp Med 2003;198:569-80.
48. + regulatory T cells through a STAT-dependentmechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
49. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008;181: 5791-802.
50. Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, et al. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 2013;210:1433-445.
51. Zhi L, Ustyugova IV, Chen X, Zhang Q, Wu MX. Enhanced Th17 differentiation and aggravated arthritis in IEX-1-deficient mice by mitochondrial reactive oxygen species-mediated signaling. J Immunol 2012;189: 1639-47.
52. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-32.
53. Kieper WC, Troy A, Burghardt JT, Ramsey C, Lee JY, Jiang HQ, et al. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J Immunol 2005;174:3158-63.